- Home
- TPST
as 07-26-2024 4:00pm EST
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | BRISBANE |
| Market Cap: | 48.7M | IPO Year: | N/A |
| Target Price: | $20.75 | AVG Volume (30 days): | 516.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.17 - $9.77 | Next Earning Date: | 08-08-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Tempest Therapeutics Inc. (TPST)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Brady Stephen R | TPST | President and CEO | Jul 3 '24 | Buy | $2.11 | 35,000 | $73,850.00 | 46,376 | SEC Form 4 |
Latest Tempest Therapeutics Inc. News
TPST Breaking Stock News: Dive into TPST Ticker-Specific Updates for Smart Investing
Argus Research
18 days ago
Daily – Vickers Top Buyers & Sellers for 07/09/2024
Argus Research
22 days ago
Daily – Vickers Top Buyers & Sellers for 07/05/2024
Argus Research
24 days ago
Daily – Vickers Top Buyers & Sellers for 07/03/2024
GlobeNewswire
a month ago
Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
GlobeNewswire
a month ago
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
GlobeNewswire
2 months ago
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Tempest to Participate in Upcoming Investor Conferences
GlobeNewswire
3 months ago
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
Compare TPST vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TPST Tempest Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.